The seminal discovery that a subset of patients harbouring somatic mutations of the EGFR exhibits dramatic responses to the orally bioavailable receptor tyrosine kinase inhibitor gefitinib or erlotinib [65-67] spearheaded the shift in thinking about how to target NSCLC more effectively. Here, EGFR is linked to non-small cell lung carcinoma.